ClinicalTrials.gg
CompletedNCT05587322Updated Oct 13, 2026

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease

A Phase 3 interventional study of BLI5100 and Placebo in Non-erosive Reflux Disease, sponsored by Braintree Laboratories. Completed at 112 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Braintree Laboratories (part of Sebela Pharmaceuticals) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2023, 3 years 1 month ago, and no results have been posted to the registry.
Updated Oct 13, 2026Enrollment updatedPrimary outcomes revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
788
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The objective of the Treatment Phase of the study is to evaluate the safety and efficacy of 4 weeks of once daily oral administration of BLI5100 low dose, BLI5100 high dose, or placebo in patients with NERD. The objective of the Extension Phase of the study is to evaluate the safety of extended exposure to once daily oral administration of BLI5100 low dose and BLI5100 high dose in patients with NERD.

02

Conditions studied

  • Non-erosive Reflux Disease
03

In context

Non-Erosive Reflux Disease

47 studies on the registry are indexed under Non-Erosive Reflux Disease; 8 are open to participants now.

This study's enrollment of 788 is above the median of 160 across 34 interventional studies indexed under Non-Erosive Reflux Disease.

Browse Non-Erosive Reflux Disease studies →

Lead sponsor

Braintree Laboratories is the lead sponsor of 49 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 7 (70%) have results posted.

First submitted after Braintree Laboratories became part of Sebela Pharmaceuticals.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 years at the time of signing ;
  2. Have experienced heartburn (burning sensation, pain at posterior bony thorax) for at least 6 months prior to Screening;
  3. Have documented history of symptomatic GERD;
  4. Have no mucosal break(s) on the upper GI endoscopy performed during Screening;
  5. Have reported heartburn on ≥4 days during any consecutive 7-day period of the Screening Period as recorded in the eDiary;
  6. Able to understand and comply with the protocol requirements;
  7. Willing and able to provide written informed consent at Screening;
  8. A female of defined as a non- female who has not had a bilateral oophorectomy or medically documented ovarian failure; or If a female of , agrees to use an acceptable form of and avoid egg donation from the Screening Visit until 6 months after the last dose of study drug.
  9. If a male, agrees to use an acceptable form of birth control from the Screening Visit until 3 months after the last dose of study drug.
  10. If a male, agrees to abstain from sperm donation through 3 months after administration of the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Unable to undergo an upper GI endoscopy;
  2. Presence of esophageal stricture, gastroesophageal varix (including post sclerotherapy or ligation), untreated Barrett's esophagus, gastric bleeding, infection, tumor, or gastric or duodenal ulcer on the upper GI endoscopy;

    o Note: Patients with diagnosis of Schatzki's ring (mucosal tissue ring around lower esophageal sphincter) are eligible to participate.

  3. Diagnosed with erosive gastroesophageal reflux disease, acute upper GI bleeding, gastric ulcer or duodenal ulcer, or acute gastritis within 2 months prior to the upper GI endoscopy;
  4. Alarm symptoms such as odynophagia, severe dysphagia, upper GI bleeding, weight loss, anemia, or hematochezia within 4 weeks prior to Screening, unless the presumed is ruled out;
  5. History or suspicion of functional upper gastrointestinal disorders, such as:

    • Functional heartburn, as described in the Rome IV criteria, or
    • Functional dyspepsia, as described in the Rome IV criteria.
  6. History of a connective tissue disorder associated with GI symptoms (eg, scleroderma or systemic lupus erythematous) or inflammatory bowel disease, or documented history of delayed gastric emptying;
  7. History of acid-suppressive, esophageal, or gastric surgery;

    o Note: This is not applicable to appendectomy, cholecystectomy, or endoscopic excision of benign tumor.

  8. History of malignancy within the past 5 years (with the exception of resected basal cell or squamous cell carcinoma of the skin);

    o Note: This is not applicable to patients who had complete response or pathological complete response and whose tumor had not recurred for at least 5 years from the date of last treatment, or patients whose tumor had been removed by endoscopic resection without any findings indicating recurrence of the tumor within 3 years.

  9. History of an allergic disease, or or intolerance to the active ingredient or of the study drug;
  10. History of alcoholism, chronic opiate use, or substance addiction in the 12 months before Screening or a positive urine drug screen for opiates or substances of abuse;

    • Note: Patients on prescribed opioids are eligible to participate if they have been on a stable dose for >3 months prior to Screening.
    • Note: Retesting of a positive urine drug screen requires Medical Monitor approval. Positive urine drug screen for all drugs will require verification of prescription for the positive tested substance.
  11. Presence of manic-depression, anxiety disorder, panic disorder, somatoform disorder, personality disorder, or other psychological disorder;

    o Note: A diagnosis of manic-depression, anxiety disorder, panic disorder, somatoform disorder, personality disorder, or other psychological disorder is not exclusionary, as long as the patient is asymptomatic and well-controlled on stable treatment (ie, stable dose for >6 months prior to Screening), including non-medical therapy.

  12. Current use of antipsychotics, antidepressants, anxiolytics, or prescription sleeping medications, with the exception of a stable dose for >6 months prior to Screening;
  13. Use of any gastric acid-suppressive agents, including PPIs, within 2 weeks prior to the upper GI endoscopy at Screening;
  14. Use of 2 or more commercial doses of reflux esophagitis-related medications (including H2 blockers, prostaglandins, mucosal protective agents, prokinetics, and antacids) within 1 week prior to the upper GI endoscopy at Screening;
  15. Requirement of persistent (>3 times per week for >30 days) use of non-steroidal anti-inflammatory drugs (NSAIDs) during the course of the study;

    o Note: Low-dose (≤100 mg/day) aspirin is allowed provided that it has been used for prophylaxis prior to study participation.

  16. If a female, is pregnant, breastfeeding, or planning to become pregnant during the study or within 6 months after the last dose of study drug;
  17. Positive test result for , surface antigen, or virus at Screening;
  18. Positive test result for H. pylori at Screening or diagnosis and treatment of H. pylori within 4 to 6 weeks prior to Randomization;

    o Note: Patients who test positive for H. pylori at Screening will be offered treatment according to local standard of care and may be re-screened for eligibility following completion of treatment.

  19. Abnormal laboratory results with clinical relevance at Screening as follows:

    • (AST), alanine aminotransferase (ALT), or alkaline phosphatase level of ≥2 × (ULN);
    • Total level of ≥2 × ULN, unless Gilbert's syndrome is confirmed when direct bilirubin is ≤0.3 mg/dL;
    • Estimated \<30 mL/min; or
    • Serum magnesium \<lower limit of normal.
  20. Abnormal of clinical significance (eg, major arrhythmia, multifocal premature ventricular contractions, or 2° atrioventricular block anomaly);
  21. Presence of any gastric acid hypersecretory conditions, such as Zollinger-Ellison syndrome;
  22. Involvement in another clinical study within 4 weeks of initiation of study drug; or
  23. Any other condition that would confound study endpoints or adversely affect patient compliance with the study procedures in the medical judgment of the Investigator or Medical Monitor based on previous medical history or findings on Screening assessments .
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
788 participants (actual)

Study arms

  • Experimental
    BLI5100 Low Dose

    During the Treatment Period, patients will take BLI5100 low dose once daily, orally, for 8 weeks. During the Extension Period, patients will continue to take BLI5100 low dose once daily, orally, for 20 weeks.

    Drug: BLI5100

  • Experimental
    BLI5100 High Dose

    During the Treatment Period, patients will take BLI5100 high dose once daily, orally, for 8 weeks. During the Extension Period, patients will continue to take BLI5100 high dose once daily, orally, for 20 weeks.

    Drug: BLI5100

  • Placebo comparator
    Placebo

    During the Treatment Period, patients will take placebo once daily, orally, for 8 weeks. In the Extension Phase, patients who received placebo in the Treatment Phase will be re-randomized to receive either BLI5100 low dose or BLI5100 high dose to take once daily, orally, for 20 weeks.

    Drug: Placebo

Interventions

  • Orally via tablet

  • DrugPlacebo

    Orally via tablet

06

What researchers measure

Primary outcomes

  1. Percentage of 24-Hour Heartburn Free Days Through Week 4 of Treatment Phase

    Participants were assigned an electronic heartburn diary (eDiary) to complete twice daily, in the morning (AM) and evening (PM). A heartburn-free day was defined as a day with no heartburn reported in the morning (AM) or evening (PM) diary entries.

    Time frame: 4 Weeks

Secondary outcomes

  1. Percentage of Days Without Nighttime Heartburn Through Week 4 of Treatment Phase

    A heartburn-free day was defined as a day with no heartburn reported in the evening (PM) diary entry.

    Time frame: 4 Weeks

07

Study locations

112 sites
  • Research Site 24
    Huntsville, Alabama 35801, United States
  • Research Site 132
    Peoria, Arizona 85381, United States
  • Research Site 62
    Phoenix, Arizona 85018, United States
  • Research Site 27
    Tucson, Arizona 85712, United States
  • Research Site 87
    Little Rock, Arkansas 72211, United States
  • Research Site 117
    North Little Rock, Arkansas 72117, United States
  • Research Site 51
    Arcadia, California 91006, United States
  • Research Site 126
    Bakersfield, California 93309, United States
  • Research Site 66
    Bell Gardens, California 90201, United States
  • Research Site 19
    Canoga Park, California 91304, United States
  • Research Site 94
    Chula Vista, California 91910, United States
  • Research Site 10
    Huntington Park, California 90255, United States
  • Research Site 55
    La Mesa, California 91942, United States
  • Research Site 120
    Long Beach, California 90808, United States
  • Research Site 72
    Los Angeles, California 90017, United States
  • Research Site 54
    Los Angeles, California 90057, United States
  • Research Site 18
    Mission Viejo, California 92691, United States
  • Research Site 14
    San Diego, California 92120, United States
  • Research Site 85
    Santa Ana, California 92703, United States
  • Research Site 13
    Santa Ana, California 92704, United States
  • Research Site 41
    Santa Maria, California 93458, United States
  • Research Site 112
    Aurora, Colorado 80012, United States
  • Research Site 89
    Littleton, Colorado 80120, United States
  • Research Site 74
    Boca Raton, Florida 33434, United States
  • Research Site 108
    Cooper City, Florida 33024, United States
  • Research Site 91
    Doral, Florida 33172, United States
  • Research Site 03
    Hialeah, Florida 33013, United States
  • Research Site 78
    Homestead, Florida 33030, United States
  • Research Site 09
    Lake City, Florida 32055, United States
  • Research Site 23
    Maitland, Florida 32751, United States
  • Research Site 38
    Miami, Florida 33134, United States
  • Research Site 43
    Miami, Florida 33136, United States
  • Research Site 81
    Miami, Florida 33142, United States
  • Research Site 67
    Miami, Florida 33155, United States
  • Research Site 92
    Miami, Florida 33173, United States
  • Research Site 31
    Miami, Florida 33185, United States
  • Research Site 71
    Miami, Florida 33186, United States
  • Research Site 42
    Miami Lakes, Florida 33014, United States
  • Research Site 17
    New Port Richey, Florida 34653, United States
  • Research Site 90
    Ocoee, Florida 34761, United States
  • Research Site 107
    Orlando, Florida 32807, United States
  • Research Site 05
    Palmetto Bay, Florida 33157, United States
  • Research Site 95
    St. Petersburg, Florida 33709, United States
  • Research Site 11
    Sunrise, Florida 33351, United States
  • Research Site 46
    Viera, Florida 32940, United States
  • Research Site 04
    Marietta, Georgia 30060, United States
  • Research Site 59
    Sandy Springs, Georgia 30328, United States
  • Research Site 101
    Idaho Falls, Idaho 83404, United States
  • Research Site 102
    Downers Grove, Illinois 60515, United States
  • Research Site 01
    Gurnee, Illinois 60031, United States
  • Research Site 113
    Northbrook, Illinois 60062, United States
  • Research Site 02
    Oak Lawn, Illinois 60453, United States
  • Research Site 135
    South Bend, Indiana 46635, United States
  • Research Site 125
    Covington, Louisiana 70433, United States
  • Research Site 45
    Houma, Louisiana 70363, United States
  • Research Site 12
    Marrero, Louisiana 70072, United States
  • Research Site 124
    Metairie, Louisiana 70006, United States
  • Research Site 48
    Metairie, Louisiana 70006, United States
  • Research Site 34
    New Orleans, Louisiana 70127, United States
  • Research Site 25
    West Monroe, Louisiana 71291, United States
  • Research Site 93
    Chesterfield, Michigan 48047, United States
  • Research Site 111
    Chesterfield, Missouri 63005, United States
  • Research Site 137
    Columbia, Missouri 65201, United States
  • Research Site 06
    Las Vegas, Nevada 89106, United States
  • Research Site 73
    Las Vegas, Nevada 89109, United States
  • Research Site 127
    Las Vegas, Nevada 89128, United States
  • Research Site 64
    Reno, Nevada 89511, United States
  • Research Site 129
    Englewood, New Jersey 07631, United States
  • Research Site 130
    Freehold, New Jersey 07728, United States
  • Research Site 131
    Jackson, New Jersey 08527, United States
  • Research Site 35
    Brooklyn, New York 11235, United States
  • Research Site 07
    Great Neck, New York 11023, United States
  • Research Site 28
    Hartsdale, New York 10530, United States
  • Research Site 58
    New York, New York 10021, United States
  • Research Site 49
    New York, New York 10033, United States
  • Research Site 40
    Rochester, New York 14609, United States
  • Research Site 75
    Fayetteville, North Carolina 28304, United States
  • Research Site 69
    Mount Airy, North Carolina 27030, United States
  • Research Site 116
    Salisbury, North Carolina 28144, United States
  • Research Site 20
    Columbus, Ohio 43213, United States
  • Research Site 88
    Columbus, Ohio 43215, United States
  • Research Site 109
    Mentor, Ohio 44060, United States
  • Research Site 118
    Springboro, Ohio 45066, United States
  • Research Site 110
    Westlake, Ohio 44145, United States
  • Research Site 61
    North Charleston, South Carolina 29405, United States
  • Research Site 128
    Hermitage, Tennessee 37076, United States
  • Research Site 114
    Kingsport, Tennessee 37663, United States
  • Research Site 60
    Nashville, Tennessee 37203, United States
  • Research Site 103
    Nashville, Tennessee 37211, United States
  • Research Site 50
    Shelbyville, Tennessee 37160, United States
  • Research Site 115
    Beaumont, Texas 77701, United States
  • Research Site 100
    Bellaire, Texas 77401, United States
  • Research Site 98
    Dallas, Texas 75230, United States
  • Research Site 99
    Forney, Texas 75126, United States
  • Research Site 68
    Katy, Texas 77494, United States
  • Research Site 29
    Lewisville, Texas 75057, United States
  • Research Site 32
    Pearland, Texas 77584, United States
  • Research Site 30
    Red Oak, Texas 75154, United States
  • Research Site 22
    San Antonio, Texas 78209, United States
  • Research Site 26
    San Antonio, Texas 78229, United States

Showing the first 100 of 112 sites. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Oct 2023, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2022
First posted
Oct 20, 2022
StartActual
Sep 6, 2022
Primary completionActual
Oct 13, 2023
CompletionActual
Apr 23, 2024
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 United States)
  • Research Site 95 · St. Petersburg, United States
  • Research Site 65 · Sandy City, United States
Show 2 removed
  • Research Site 95 · Saint Petersburg, United States
  • Research Site 65 · Sandy, United States
Oct 13, 2026
Enrollment
800→788
Oct 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPercentage of 24-hour heartburn-free daysHour Heartburn Free Days Through Week 4 of Treatment PhaseTime frame: 4 Weeks
Oct 13, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Percentage of patients with complete resolution of main symptoms (heartburn and regurgitation)Now Percentage of Days Without Nighttime Heartburn Through Week 4 of Treatment PhaseTime frame: 4 Weeks
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 United States)
    • Research Site 95 · St. Petersburg, United States
    • Research Site 65 · Sandy City, United States
    Show 2 removed
    • Research Site 95 · Saint Petersburg, United States
    • Research Site 65 · Sandy, United States
    Enrollment 800→788
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPercentage of 24-hour heartburn-free daysHour Heartburn Free Days Through Week 4 of Treatment PhaseTime frame: 4 Weeks
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Percentage of patients with complete resolution of main symptoms (heartburn and regurgitation)Now Percentage of Days Without Nighttime Heartburn Through Week 4 of Treatment PhaseTime frame: 4 Weeks
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05587322
Responsible party
Sponsor
First posted
Oct 20, 2022
Start date
Sep 6, 2022
Primary completion
Oct 13, 2023
Completion
Apr 23, 2024
Last update
Oct 13, 2026

Study contacts

Leah Hollins
study director · Braintree Laboratories / Sebela Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion